R-GNE-140 - CAS# 2003234-63-5 size:2mg solid 2014 the FDA approved the

2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg (trade name Harvoni)

IL-1b and IL-18

These results indicate that synthetic REV-ERB ligands that pharmacologically target the circadian rhythm may be beneficial in the treatment of sleep disorders as well as metabolic diseases

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolitesin Cancer Cells andInduce High Levels of Bystander Killing

R-GNE-140 - CAS# 2003234-63-5 size:2mg solid 2014 the FDA approved theR GNE 140, CAS No. 2003234 63 5, a novel potent lactate dehydrogenase (LDHA) inhibitor with IC50 3nM for LDHA and 5 nM for LDHB. In MIA PaCa 2 human pancreatic cells, LDHA inhibition rapidly affected global metabolism, although cell death only occurred after 2 d of continuous LDHA inhibition. Pancreatic cell lines that utilize oxidative phosphorylation (OXPHOS) rather than glycolysis were inherently resistant to GNE 140, but could be resensitized to